This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
C

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macroscopic, Resectable Stage 3 Melanoma"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Christian Blank
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Christian Blank
251 views
June 14, 2024

Chapters

Neoadjuvant Therapy in Stage III Melanoma

00:00

NADINA Trial: Efficacy & Survival Data

02:16

Toxicity & Quality of Life Assessment

05:19

0 Comments
Login to view comments. Click here to Login

2024 ASCO® Annual Meeting Insights Hub: Skin Videos

05:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Biomarker Analysis & Updated Clinical…

Feat. L. Burton
35:23
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

Feat. S. Patel
24:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and A…

Feat. Z. Eroglu
View All

Related Content

AUTOPLAY
Melanoma Research Foundation

13th Annual CURE OM Global Science Meeting

Wed, Oct 9, 2024
See 1 other
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
24:14
Masterclasses in Dermatology

Advances in the Treatment of Melanoma

Feat. D. Fisher
35:23
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

Feat. S. Patel
12:46
Stanford Medicine

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Feat. A. Betof Warner
09:26
Oncology Data Advisor

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Feat. M. Hadfield
22:58
Tarek Haykal

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

11:05
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, …

Feat. D. Johnson
25:29
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Insights in Melanoma"

Feat. O. Hamid
09:54
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Ou…

Feat. H. Tawbi
18:28
Vanderbilt University Medical Center (VUMC)

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Feat. D. Johnson
14:42
Jeff Yorio

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

03:55
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib …

Feat. A. Hauschild
24:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and A…

Feat. Z. Eroglu
11:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We B…

Feat. P. Corrie
22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
07:23
Mees Egeler

Long-Term Side Effects Associated With IO Treatment vs. TT in Adjuva…

17:07
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis

Melanoma Brain Metastases: Successes, Failures, and Future Opportuni…

Feat. M. Postow
14:23
Alexander Van Akkooi

Advantages & Disadvantages of Adjuvant IO vs. Targeted Treatment…

28:32
West Virginia State Rheumatology Society

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

Feat. J. Bustamante
10:39
University of Colorado Department of Medicine

Cardio-Oncology: Definitions and Scope

Feat. L. Kondapalli